CG Oncology shares traded lower Friday as the market focused on financing overhang rather than near-term clinical headlines. The key pressure point is the company’s expanded at-the-market (ATM) equity program, which increases the potential supply of shares and can weigh on the stock when investors anticipate incremental selling.

The company filed an amended prospectus to increase the maximum aggregate offering size of its ATM program from $250 million to up to $550 million, meaning the company can sell stock from time to time into the market through its sales agent. Even if the company does not immediately sell shares, the expanded authorization can be interpreted as higher potential dilution and a more persistent technical headwind, especially on down or risk-off tape. The prospectus supplement also quantifies dilution at an assumed price level, underscoring how meaningful the impact could be for new buyers if the program is utilized.

Investors have recent evidence that the ATM is not merely a shelf. In its February 27, 2026 business update, CG Oncology disclosed it sold 2,343,967 shares through the ATM in Q4 2025 for about $98.4 million in net proceeds and sold another 3,623,101 shares in January 2026 for about $188.0 million in net proceeds. That pattern can make day-to-day weakness more easily attributed to incremental supply concerns, even in the absence of a new same-day press release.